APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease
The randomized, unblinded trial will treat 24 patients for seven days to obtain preliminary data on the impact of rhACE2 on biological, physiologic, and clinical outcomes, as well as safety in patients with severe SARS-CoV-2 infection. These data will be assessed to ascertain whether a Phase 2B clinical trial in a larger number of patients is warranted.
The trial is being supported by a global team of leading experts: Intensive care specialist, Prof. Arthur Slutsky, Scientist, St. Michael’s Hospital, Toronto, and Prof. of Medicine, Surgery and Biomedical Engineering at the University of Toronto (Toronto, Canada) and Prof. Haibo Zhang, Prof. of Anesthesiology, St. Michael’s Hospital, University of Toronto; Prof. Nanshan Zhong and Prof. Yimin Li, both of the Guangzhou Institute of Respiratory Health and leading physicians in fight against COVID-19 in China, will oversee the trial; and Prof. Josef Penninger, Scientific Director and Professor of the Life Science Institute of the University of British Columbia, Canada.
“To address this unfortunate crisis and dreadful disease our team has at short notice been able to bring together a worldwide team of experts and scientists. Our drug candidate APN01 has been proven safe and well tolerated in patients in previous clinical PhI and PhII trials. We are delighted and proud that we can now start treating infected patients in China.” said Peter Llewellyn-Davies, Chief Executive Officer of APEIRON Biologics AG.
“Our lab provided the first in vivo proof that ACE2, which we had cloned and made the first mutant mice, is the essential receptor for the SARS-CoV-2 and that ACE2 has the potential to protect the lung from injury by collaborating with Prof. Chengyu Jiang at PUMC in Beijing. I am excited that based on our research and developments, the potential of APN01 (soluble human ACE2 protein) for the treatment of patients suffering from the novel coronavirus infection is now being explored in clinical trials,” stated Prof. Penninger, MD, co-inventor of APN01, founder of APEIRON, member of its supervisory board and Professor at the University of British Columbia.
“ACE2 has been shown to be essential for early viral infection of the SARS-CoV virus, which spread rapidly around the world in 2003. The novel coronavirus SARS-CoV-2 also relies on the ACE2 receptor to infect human cell. Thus, treatment with recombinant human ACE2, can be used to block viral spread, and may minimize lung injury, and multiple organ dysfunction, and ultimately decrease mortality in patients with COVID-19.” explained Prof. Slutsky.
After seven days of treatment, the trial data will be evaluated and potential further clinical development will be assessed by APEIRON and the IIT team.
This trial cooperation has been supported by Dr. Liqun Zhang and team of Angalpharma Co., Ltd (Suzhou, China), for coordinating the Chinese clinical trial with the support of dMed Pharmaceutical Co., a CRO team based in China.
Other news from the department research and development
Biofrontera transfers clinical research to the U.S.
"We can be much more flexible in our strategy to expand our market presence in Europe thanks to the newly defined cost structure"
BASF to research on alternatives to animal testing on behalf of the European Chemicals Agency
Number of animal experiments required for safety assessments of chemical substances to be further reduced
Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I
A milestone on the pathway to Lab 4.0: A new standard for the smart lab
SPECTARIS presents the first industrial communication standard for laboratory and analytical devices
Using artificial intelligence to discover therapeutic antibodies
Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics
Eppendorf and Neste forge strategic partnership to develop new line of renewable lab plastics
A sustainable choice for labs
UK approves world's first therapy with gene scissors
Developers of the Crispr method were awarded the Nobel Prize in 2020: a drug using the gene scissors has now been approved for the first time
Novel protein to prevent immune system attacks on own body
1.2 million euros for immunology start-up
Startup HyPhoX develops miniaturized biosensors with support from BAM
"The innovative thing about our sensor is that we combine optical, electrical and biochemical analytics on one chip, and we do it in a handy, portable device"
Collaboration to develop vaccine against Helicobacter pylori
Core Facility Animal Models and start-up company Iguana cooperate
Fraunhofer IPA transfers rights to use laboratory robot KEVIN United Robotics Group
KEVIN can be flexibly and intuitively integrated into laboratory infrastructures and automates processes
Dresden-based start-up "DermaPurge" develops skin cleanser for hazardous substances
Global Handwashing Day
SAS accelerates delivery of novel medicines using AI and analytics
Cooperation with AstraZeneca for more innovation in clinical research
New incubator to promote drug discovery and create new therapeutics companies in Singapore
Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch "65LAB"
Groundbreaking: Takeda builds lab of the future in Vienna
New research and development laboratory in Vienna's Donaustadt district
New muscle therapy gets fast-track boost
Berlin start-up could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process
Most read news
mRNA therapeutic successfully combats ovarian cancer
The mRNA therapeutic successfully combated cancerous cells and tumors in vitro as well as metastases in mice
The secret of whales: How giant whales defy cancer
Study of gigantism in whales provides clues to genomic mechanism involved in tumor suppression
A virus that kills sleepers
Researchers have found a virus that kills dormant bacteria: This rare discovery could help to combat germs that can’t be treated with antibiotics alone
Microbe of the Year 2023: Bacillus subtilis – for health and technology
Already, Bacillus subtilis is indispensable in many industries, and many more innovations are expected
Making Ends Meet: Researchers Find That a Protein Superglue is Crucial for DNA Damage Repair
New Understanding for Cancer Treatments
A standard blood test can predict a heart attack
Using the results of a standard blood test and an online tool, you can find out if you are at increased risk of having a heart attack within six months
Learning from Nature: How a fungus makes a hard job easier
Researchers analyze a fungal biosynthetic pathway and discover a capable enzyme
Innovative microscopy technique reveals secrets of lipid synthesis inside cells
Two-color infrared photothermal microscopy (2C-IPM) opens new avenues for long-term study of lipid metabolism in living cells
New agent blocks stress response
In the future, this could enable stress-related conditions such as chronic depression to be treated much more specifically and with fewer side effects
Artificial cartilage with the help of 3D printing
New approach to producing artificial tissue works with cells in microstructures from the 3D printer
Destroying Tumor Cells with Calcium
Activating calcium channels leads to a deadly influx of calcium ions into tumor cells
More news from our other portals
Battery start-up is developing safe, long-lasting thin-film solid-state batteries that can be charged and discharged in one minute
BTRY raises CHF 900,000 in pre-seed funding for the development of an innovative solid-state battery
Mystery of Novel Clove-Like Off-Flavor in Orange Juice Solved
Tracking down off-flavours using techniques such as gas chromatography-olfactometry and aroma extract dilution analysis
World first: The first CO2-negative biofuel comes from Germany
Start-up Carbon Farming Germany revolutionizes fuel production with BeyondZero
Planned EU legislation on packaging threatens popular seasonal confectionery
Federal Association of the German Confectionery Industry fears the end of chocolate Easter bunnies & Co.
Chemists are on the hunt for the other 99 percent
New mass spectrometry combo offers promise for tapping nature’s unknown chemical universe
Green steel from toxic red mud
An economical process with green hydrogen can be used to extract CO2-free iron from the red mud generated in aluminium production
BASF and Envision Energy enter a collaboration to drive sustainable energy solutions
Collaboration to accelerate conversion of green hydrogen and CO2 to e-methanol
Eckes-Granini further expands important out-of-home business segment
Market share gains and double-digit sales growth in 2023
GPT-3 for chemical research
Researchers develop fast and user-friendly language model for chemical tasks
Microgreens made to order
Italian scientists have tailored iodine and potassium content of radishes, peas, rocket and chard
Revolutionizing batteries: Coffee grounds power high-performance sodium-ion anodes
Using coffee waste as a precursor material for hard carbon synthesis
Greetings from the island of enhanced stability: The quest for the limit of the periodic table
A fresh view on new superheavy elements
Detect 'forever chemicals' in under 3 minutes
New lab-based method to detect traces of PFAS from food packaging material, water and soil samples